Harlow Council and One Nucleus would like to announce that after eight successful years the M11 Health Enterprise Forum will join the London Stansted Cambridge Consortium (LSCC) in its efforts to promote the Innovation Corridor https://innovationcorridor.uk/ that exists from King's Cross to Peterborough.
In addition, Professor Gino Martini Chief Scientist of the Royal Pharmaceutical Society and resident of Harlow and co-founder of the M11 Health Enterprise Forum will join the LSCC as Deputy Chair.
Professor Martini commenting on the changes 'The addition of the M11…
Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels.…
Leading Cambridge and international intellectual property (IP) firm Marks & Clerk is to host the Cambridge IP Summit, taking place on Thursday 10 October at the Hilton Hotel, Cambridge.
The event aims to build upon the success of last year’s summit, which brought leading businesses from Cambridge and beyond together to discuss how to protect high-tech innovation.
The one day event provides a forum for in-house IP teams, general counsel, investors, CEOs, CTOs and senior decision makers to come together to discuss and analyse the key issues impacting innovative and technology driven…
Westbury, NY – Oct. 2, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Lori Ball as its chief operating officer (COO). In her new position, Ms. Ball will be responsible for providing leadership and strategic direction on operational and business decisions, including growth planning, business and organizational development, risk management, and quality control.
“Lori has the requisite business expansion, global supply chain and regulatory expertise to help us take BioIVT through the next phase of its…
Louvain la Neuve, Belgium, 1st October 2019 / Sciad Newswire / N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and Dashboard Apps in order to design, plan and monitor their clinical trial supply chain.
John Murray, Supply Chain Transformation Lead at AstraZeneca, commented: “N-SIDE’s Suite provides a tremendous opportunity for AstraZeneca to collaborate across key areas of…
Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.
Martin Bertschinger…
Today, Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC Board on 1st October 2019.
Clare is Head of Corporate Development at Syncona Investment Management Limited and has 15 years’ experience as a specialist healthcare and life sciences corporate financier in London. She joined Syncona from Numis Securities, where she was a Managing Director, Healthcare & Life Sciences,…
Cambridge, UK; September 27, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will present a poster today that details an expanding body of evidence for the dual mechanism-of-action of the company’s anti-ICOS program, KY1044. The poster will be presented at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON), being held at the Espace Grande Arche in Paris September 25-28, 2019.
KY1044 is a novel fully-human antibody that binds ICOS and is designed to both deplete intratumoral regulatory T cells and stimulate…
AMSBIO has introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.Targeted cancer therapy represents a promising new cancer treatment, one which delivers drugs in specific carriers and interferes with the specific target molecules that play a critical role in tumour growth and progression. Exosomes expressing specific surface markers (among them CD81, CD63, and CD9) have been found to play roles in cancer progression and tumorigenesis as a transporter of miRNA. As a delivery system, they can therefore potentially be…